Guidelines for Managing Alzheimer's Disease: Part II. Treatment

JEFFREY L. CUMMINGS, M.D., and JANET C. FRANK, DR.P.H., University of California, Los Angeles, School of Medicine, Los Angeles, California DEBRA CHERRY, PH.D., Alzheimer's Association, Los Angeles, California
NEAL D. KOHATSU, M.D., M.P.H., California Department of Health Services, Sacramento, California
BRYAN KEMP, PH.D., University of Southern California Rancho Los Amigos National Rehabilitation Center, Los Angeles, California
LINDA HEWETT, PSY.D., University of California, San Francisco, School of Medicine, San Francisco, California
BRIAN MITTMAN, PH.D., Veterans Administration Healthcare System, Los Angeles, California

Once the clinical diagnosis of Alzheimer's disease has been made, a treatment plan must be developed. This plan should include cholinesterase inhibitor therapy to temporarily improve cognition or slow the rate of cognitive decline, management of comorbid conditions, treatment of behavioral symptoms and mood disorders, provision of support and resources for patient and caregiver, and compliance with state-mandated reporting requirements for driving impairment and elder abuse. The primary caregiver can be a valuable ally in communication, management of care, and implementation of the care plan. Patient symptoms and care needs change as Alzheimer's disease progresses. In the early stage of the disease, the family physician should discuss realistic expectations for drug therapy, solicit patient and family preferences on future care choices, and assist with advance planning for future care challenges. In the middle stage, the patient may exhibit behavioral symptoms that upset the caregiver and are difficult to manage. When the patient is in the advanced stage of Alzheimer's disease, the caregiver may need support to provide for activities of daily living, help in making a difficult placement decision, and guidance in considering terminal care options. Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease. (Am Fam Physician 2002;65:2525-34. Copyright© 2002 American Academy of Family Physicians.)

A PDF version of this document is available. Download PDF now (10 pages / 105 KB). More information on using PDF files.

The management guidelines discussed in this two-part article and summarized in part I¹ are designed to assist family physicians in directing the care of patients and their caregivers after Alzheimer's disease has been diagnosed. Part I addressed the assessment and monitoring of patients and caregivers. Part II focuses on the selection and provision of appropriate treatments for the multiple symptoms patients experience over the course of Alzheimer's disease.

Development of a Management Plan

When Alzheimer's disease has been diagnosed, a comprehensive management plan should be developed. As the disease progresses, this plan will have to be modified to address new issues, exacerbations of other health conditions, and end-of-life decisions.

A comprehensive management plan should be developed as soon as possible after Alzheimer's disease is diagnosed. This plan should encompass the values and preferences of the patient and family, and should also address comorbid conditions. As the disease progresses, the management plan should be modified to address new issues.

Management consists of both pharmacologic and nonpharmacologic interventions, as well as referrals to social service agencies and support resources such as the Alzheimer's Association.² The family physician plays a key role in linking the family to community resources and other health care and social service providers who will help in implementing the overall care plan.

Treatment

COGNITIVE DEFICITS

Cholinesterase Inhibitors. Treatment with cholinesterase inhibitors can provide modest improvement of symptoms, temporary stabilization of cognition, or reduction in the rate of cognitive decline in some patients with mild to moderate Alzheimer's disease. Approximately 20 to 35 percent of patients treated with these agents exhibit a seven-point improvement on neuropsychologic tests (equivalent to one year's decline and representing a 5 to 15 percent benefit over placebo).³ Before treatment is initiated, it is important to communicate the expected (modest) benefits of cholinesterase inhibitors to the patient and family.

Four cholinesterase inhibitors are currently available: donepezil (Aricept), rivastigmine (Exelon), galantamine (Reminyl), and tacrine (Cognex). These agents raise acetylcholine levels in the brain by inhibiting acetylcholinesterase. No head-to-head studies have compared the efficacy of the cholinesterase inhibitors, and their main differences are their side effect profiles and administration regimens. Information about these agents is summarized in Table 1.

TABLE 1 Cholinesterase Inhibitors for the Treatment of Cognitive Deficits in Patients with Mild to Moderate Alzheimer's Disease Drug Suggested dosage Side effects Specific cautions Donepezil (Aricept) Initial dosage is 5 mg once daily; if necessary, dosage can be increased to 10 mg once daily after 4 to 6 weeks. Mild side effects, including nausea,vomiting, and diarrhea; these effects can be reduced by taking donepezil with food. Initial increase of agitation in some patients; agitation typically subsides after a few weeks. Conflicting evidence about possible interactions with cimetidine (Tagamet), theophylline, warfarin (Coumadin), and digoxin(Lanoxin) Rivastigmine (Exelon) Initial dosage of 1.5 mg twice daily (3 mg per day) is generally well tolerated; dosage can be increased as tolerated but no more quickly than by 1.5 mg twice daily (3 mg per day) every 4 weeks to maximum of 6 mg twice daily (12 mg per day). Twice-daily dosing is as efficacious as thrice-daily dosing and has comparable tolerability. Nausea, vomiting, diarrhea, headaches, dizziness, abdominal pain, fatigue, malaise, anxiety, and agitation; these effects can be reduced by taking rivastigmine with food. Weight loss Interacting drugs include aminoglycosides and procainamide (Procanbid). Galantamine (Reminyl) Initial dosage is 4 mg twice daily (8 mg per day) taken with the morning and eveningmeals for 4 weeks; dosage is then increased to 8 mg twice daily (16 mg per day) for atleast 4 weeks. An increase to 12 mg twice daily (24 mg per day) should be considered on an individual basis, depending on clinical benefit and tolerability. Mild side effects, including nausea, vomiting, and diarrhea; these effects can be reduced by taking galantamine with food. No apparent association with sleep disturbances (which can occur with other cholinergic treatments) Contraindicated for use in patients with hepatic or renal impairment Tacrine (Cognex) Initial dosage is 10 mg four times daily (40 mg per day) for 4 weeks; dosage is increased to 20 mg four times daily (80 mg per day) for 4 weeks, then to 30 mg four times daily (120 mg per day) for 4 weeks, etc., untilmaximum tolerated dosage is achieved. Maximum dosage is 40 mg four times daily (160 mg per day). High incidence of side effects, including gastrointestinal problems; these effects can be reduced by taking tacrine with food. Interacting drugs include theophylline and procainamide. Hepatotoxicity is a problem; hence, liver tests should be performed every other week for 16 weeks and every 3 months thereafter. Information from package inserts provided by the manufacturers of the drugs.

 

Donepezil is given once daily, beginning with a dosage of 5 mg per day, which can be increased to 10 mg per day (maximum dosage) after four weeks. Donepezil is not hepatotoxic. Adverse effects are mild (e.g., nausea, vomiting, and diarrhea) and are reduced when the medication is taken with food. Some patients may exhibit an initial increase in agitation, which subsides after the first few weeks of therapy. Studies have shown that donepezil produces clinically meaningful improvements of cognitive and global function in patients with mild to moderate Alzheimer's disease.³ Efficacy has been apparent over up to 4.9 years.⁴

Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors that have been labeled for the treatment of Alzheimer's disease. Tacrine is no longer considered first-line treatment for this condition.

Rivastigmine is initiated in a dosage of 1.5 mg twice daily. The dosage is increased by 1.5 mg twice daily (3 mg per day) as tolerated, but no more quickly than every four weeks, to a maximum of 6 to 12 mg per day.⁵ Higher dosages are more efficacious than lower dosages; no laboratory monitoring is required. Adverse effects include nausea, vomiting, diarrhea, weight loss, headaches, dizziness, abdominal pain, fatigue, malaise, anxiety, and agitation. Rivastigmine has been shown to be effective in temporarily slowing cognitive decline, improving function, and reducing behavioral and psychopathologic symptoms in patients with mild to moderate Alzheimer's disease.

The recommended starting dosage of galantamine is 4 mg twice daily, taken with morning and evening meals. After four weeks, the dosage is increased to 8 mg twice daily. An increase to 12 mg twice daily should be considered on an individual basis after assessment of clinical benefit and tolerability.⁶ The most common side effects are nausea, vomiting, and diarrhea. These adverse effects can be minimized by titrating the dosage gradually and taking the medication with meals. Improvement of cognitive and functional outcomes and behavioral symptoms has been shown for higher dosages of galantamine compared with placebo.

The pharmacologic characteristics and side effects of tacrine make it a second-line agent. Unlike the newer cholinesterase inhibitors, tacrine causes elevation of liver enzyme levels in 40 percent of treated patients; thus, biweekly liver tests are necessary during the period of dosage escalations and every three months thereafter. Because tacrine has a short half-life, it must be administered four times daily.⁷

Beneficial response to a cholinesterase inhibitor (i.e., stabilization or delayed deterioration of cognitive or behavioral problems) can be determined from the physician's global assessment of the patient, the primary caregiver's report, a neuropsychologic assessment or mental status questionnaire, or evidence of behavioral or functional changes. Brief mental status tests are relatively insensitive measures of the cognitive effects of cholinesterase inhibitors.⁸ Observation for six to 12 months is usually necessary to assess potential benefit.

Cholinesterase inhibitors should be discontinued if side effects develop and do not resolve, adherence is poor, or deterioration continues at the pretreatment rate after six to 12 months of treatment. Patients who do not respond to one cholinesterase inhibitor may respond to another.

Other Agents. One well-constructed study⁹ has shown that daily intake of 2,000 IU of vitamin E or 10 mg of selegiline (Eldepryl) may slow the progression of functional symptoms in patients with Alzheimer's disease. Current expert consensus recommends the use of vitamin E.

Epidemiologic studies have suggested that nonsteroidal anti-inflammatory drugs (NSAIDs) or estrogen replacement may delay the onset of Alzheimer's disease. Insufficient evidence is currently available to recommend treatment with NSAIDs or nutraceutical products such as Ginkgo biloba in patients with Alzheimer's disease. Substantial evidence has shown that estrogens do not benefit cognitive function after the onset of Alzheimer's disease.¹⁰

Nonpharmacologic interventions for behavior problems associated with Alzheimer's disease may enable a reduction in the dosage, duration, or complexity of required pharmacotherapy.

COMORBID CONDITIONS

Comorbid conditions are common in elderly patients with Alzheimer's disease, and optimal management of these disorders can reduce disability and maximize function.¹¹ Disorders to be considered include sensory deficits (especially deficits in vision or hearing), dental problems, and other common medical conditions affecting the elderly, such as hypertension, congestive heart failure, chronic obstructive pulmonary disease, diabetes, hypothyroidism, genitourinary conditions, and arthritis.

Depression is common in older adults, including those with Alzheimer's disease, and is often untreated. Limited but acceptable clinical evidence supports the use of antidepressants in patients with depression superimposed on Alzheimer's disease. The most useful medications are those with minimal anticholinergic side effects. Selective serotonin reuptake inhibitors, such as citalopram (Celexa) and sertraline (Zoloft), appear to be effective and have few side effects; thus, they are the agents of choice for the treatment of depression in patients with dementia.¹²

BEHAVIORAL PROBLEMS AND MOOD DISORDERS

Behavioral symptoms such as agitation and wandering become common as Alzheimer's disease progresses.¹² These behavioral symptoms are especially challenging to the primary caregiver.

Nonpharmacologic Interventions. These measures should be exhausted before drugs are used to treat behavioral symptoms and mood disorders.¹³ When drug therapy is required, concomitant nonpharmacologic interventions may enable a reduction in the dosage, duration, or complexity of treatment. Suggested nonpharmacologic interventions for use in patients with Alzheimer's disease are provided in Table 2.

TABLE 2 Nonpharmacologic Interventions for Reducing Behavioral Disturbances in Alzheimer's Disease Provide the patient with a predictable routine (i.e., exercise, meals, and bedtime should be routine and punctual). Allow the patient to dress in his or her own clothing and keep possessions. Before performing all procedures and activities, explain them to the patient in simple language. Simplify all tasks; break complex tasks into steps and provide instructions for each step. Use distraction and redirection of activities to divert the patient from problematic situations. Ensure that comorbid conditions are optimally treated. Provide a safe environment (i.e., no sharp-edged furniture, no slippery floors or throw rugs, no obtrusive electric cords). Equip doors and gates with safety locks. Install grab bars by the toilet and in the shower. Use calendars, clocks, labels, and newspapers for orientation to time. Use color-coded or graphic labels (i.e., on closets, table service, drawers) as cues for orientation in the home environment. Use lighting to reduce confusion and restlessness at night. Avoid glare from windows and mirrors, noise from a television, and household clutter. Reduce excess stimulation and outings to crowded places (overexposure to environmental stimuli can lead to agitation and disorientation). Consider using a day care program for patients with Alzheimer's disease. Register the patient in the Alzheimer's Association Safe Return Program.

 

Caregivers can be taught strategies to reduce behavioral disturbances in patients with dementing illnesses such as Alzheimer's disease.¹⁴ One approach involves the three R's (repeat, reassure, and redirect).¹⁵ With this approach, the caregiver repeats an instruction or answer to a question as needed and redirects the patient to another activity to divert attention from a problematic situation. A predictable routine is also important and may avert certain behavioral problems. For example, scheduled toileting or prompted voiding can reduce urinary incontinence.

Patients at risk for wandering should be registered in the Alzheimer's Association Safe Return Program and should be protected by appropriate use of locked doors and gates.

Pharmacologic Treatments. Pharmacologic interventions are necessary when nonpharmacologic strategies fail to reduce behavioral symptoms sufficiently. Cholinesterase inhibitors may improve these symptoms.¹⁶ If behavioral disturbances persist despite cholinesterase inhibitor therapy, use of a psychotropic agent may be necessary.

In accordance with the principles of geriatric psychopharmacology, the psychotropic agent should be initiated in a low dosage that should be increased slowly, and the patient should be monitored for side effects. The dosage should be increased until an adequate response occurs or side effects emerge. Potential drug interactions should also be considered. After behavioral disturbances have been controlled for four to six months, the dosage of psychotropic agent should be reduced periodically to determine whether continued pharmacotherapy is required.

TABLE 3 Treatment of Behavior and Mood Disorders Antipsychotic drugs Atypical antipsychotic agents   Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness   General cautions: diminished risk of developing extrapyramidal symptoms and tardive dyskinesia compared with typical antipsychotic agents   Risperidone (Risperdal) Initial dosage: 0.25 mg per day at bedtime;maximum: 2 to 3 mg per day, usually twice daily in divided doses Comments: current research supports use of low dosages; extrapyramidal symptoms may occur at 2 mg per day.   Olanzapine (Zyprexa) Initial dosage: 2.5 mg per day at bedtime; maximum: 10 mg per day, usually twice dailyin divided doses Comments: generally well tolerated   Quetiapine (Seroquel) Initial dosage: 12.5 mg twice daily; maximum: 200 mg twice daily Comments: more sedating; beware of transient orthostasis. Typical antipsychotic agents   Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness; second-line therapy in patients who cannot tolerate or do not respond to atypical antipsychotic agents   General cautions: current research suggests that these drugs should be avoided if possible, because they are associated with significant, often severe side effects involving the cholinergic, cardiovascular, and extrapyramidal systems; there is also an inherent risk of irreversible tardive dyskinesia, which can develop in 50% of elderly patients after continuous use of typical antipsychotic agents for 2 years.   Haloperidol (Haldol), fluphenazine (Prolixin), thiothixene (Navane) Dosage: varies by agent Comments: anticipated extrapyramidal symptoms; if these symptoms occur, decrease dosage or switch to another agent; avoid use of benztropine (Cogentin) or trihexyphenidyl (Artane).   Trifluoperazine (Stelazine), molindone (Moban), perphenazine (Trilafon), loxapine (Loxitane) Dosage: varies by agent Comments: agents with "in-between" side effect profile Mood-stabilizing (antiagitation) drugs   Recommended uses: control of problematic delusions, hallucinations, severe psychomotor agitation, and combativeness; useful alternatives to antipsychotic agents for control of severe agitated, repetitive, and combative behaviors   General cautions: see comments about specific agents.   Trazodone (Desyrel) Initial dosage: 25 mg per day; maximum: 200 to 400 mg per day in divided doses Comments: use with caution in patients with premature ventricular contractions.   Carbamazepine (Tegretol) Initial dosage: 100 mg twice daily; titrate totherapeutic blood level (4 to 8 mcg per mL) Comments: monitor complete blood cell count and liver enzyme levels regularly; carbamazepine has problematicside effects.   Divalproex sodium (Depakote) Initial dosage: 125 mg twice daily; titrate to therapeutic blood level (40 to 90 mcg per mL) Comments: generally better tolerated than other mood stabilizers; monitor liver enzyme levels; monitor platelets, prothrombin time, and partial thromboplastin time as indicated. Anxiolytic drugs Benzodiazepines   Recommended uses: management of insomnia, anxiety, and agitation   General cautions: regular use can lead to tolerance, addiction, depression, and cognitive impairment; paradoxic agitation occurs in about 10% of patients treated with benzodiazepines; infrequent, low doses of agents with a short half-life are least problematic.   Lorazepam (Ativan), oxazepam (Serax), temazepam (Restoril), zolpidem (Ambien), triazolam (Halcion) Dosage: varies by agent See general cautions. Nonbenzodiazepines   Buspirone (BuSpar) Initial dosage: 5 mg twice daily; maximum: 20 mg three times daily Comments: useful only in patients with mild to moderate agitation; may take 2 to 4 weeks to become effective Antidepressant drugs   Recommended uses: see comments on specific agents.   General cautions: selection of an antidepressant is usually based on previous treatment response, tolerance, and the advantage of potential side effects (e.g., sedation versus activation); a full therapeutic trial requires at least 4 to 8 weeks; as a rule, dosage is increased using increments of initial dose every 5 to 7 days until therapeutic benefits or significant side effects become apparent; after 9 months, dosage reduction is used to reassess the need to medicate; discontinuing an antidepressant over 10 to 14 days limits withdrawal symptoms. NOTE: Patients with depression and psychosis require concomitant antipsychotic medication. Tricyclic antidepressant agents   Desipramine (Norpramin) Initial dosage: 10 to 25 mg in the morning; maximum: 150 mg in the morning Comments: tends to be activating (i.e., reduces apathy); lower risk for cardiotoxic, hypotensive, and anticholinergiceffects; may cause tachycardia; blood levels may be helpful.   Nortriptyline (Pamelor) Initial dosage: 10 mg at bedtime; anticipated dosage range: 10 to 40 mg per day (given twice daily) Comments: tolerance profile is similar to that for desipramine, but nortriptyline tends to be more sedating; may be useful in patients with agitated depression and insomnia; therapeutic blood level "window" of 50 to 150 ng per mL (190 to 570 nmol per L) Heterocyclic and noncyclic antidepressant agents   Nefazodone (Serzone) Initial dosage: 50 mg twice daily; maximum: 150 to 300 mg twice daily Comments: effective, especially in patients with associatedanxiety; reduce dose of coadministered alprazolam (Xanax) or triazolam by 50%; monitor for hepatotoxicity.   Bupropion (Wellbutrin) Initial dosage: 37.5 mg every morning, then increase by 37.5 every 3 days; maximum: 150 mg twice daily Comments: activating; possible rapid improvement of energylevel; should not be used in agitated patients and those with seizure disorders; to minimize risk of insomnia, give second dose before 3 p.m.   Mirtazapine (Remeron) Initial dosage: 7.5 mg at bedtime; maximum: 30 mg at bedtime Comments: potent and well tolerated; promotes sleep, appetite, and weight gain SSRIs   Recommended uses: may prolong half-life of other drugs by inhibiting various cytochrome P450 isoenzymes   General cautions: typical side effects can include sweating, tremors, nervousness, insomnia or somnolence, dizziness, and various gastrointestinal and sexual disturbances.   Fluoxetine (Prozac) Initial dosage: 10 mg every other morning; maximum: 20 mg every morning Comments: activating, very long half-life; side effects may not manifest for a few weeks.   Paroxetine (Paxil) Initial dosage: 10 mg per day; maximum: 40 mg per day (morning or evening) Comments: less activating but more anticholinergic than other SSRIs   Sertraline (Zoloft) Initial dosage: 25 to 50 mg per day; maximum:200 mg per day (morning or evening) Comments: well tolerated; compared with other SSRIs, sertraline has less effect on metabolism of other medications.   Citalopram (Celexa) Initial dosage: 10 mg per day; maximum: 40 mg per day Comments: well tolerated; some patients experience nausea and sleep disturbances.   Fluvoxamine (Luvox) Initial dosage: 50 mg twice daily; maximum: 150 mg twice daily Comments: exercise caution when using fluvoxamine with alprazolam or triazolam. Phenethylamine   Venlafaxine (Effexor) Initial dosage: 37.5 mg twice daily; maximum: 225 mg per day in divided doses Comments: highly potent; also inhibits norepinephrine reuptake Lithium   Recommended uses: for anticycling; can also be used to augment antidepressant drugs   General cautions: at higher lithium dosages, elderly patients are prone to develop neurotoxicity.   Lithium Initial dosage: 150 mg per day Comments: blood levels of 0.2 to 0.6 mEq per L (0.2 to 0.6 mmol per L) are generally adequate and are usually achieved with dosage of 150 to 300 mg per day. Electroconvulsive therapy   Recommended uses: may be required in patients who are at risk of injuring or starving themselves, patients who are severely psychotic, and patients who cannot tolerate or do not respond to antidepressants SSRIs = selective serotonin reuptake inhibitors. Information from Roland Jacobs, M.D. Dr. Jacobs is a member of the California Workgroup on Guidelines for Alzheimer's Disease Management.

 

Specific target symptoms dictate the choice of psychopharmacologic agent. Some behaviors, such as wandering and pacing, are not amenable to drug therapy. Medications used to treat behavioral disturbances and mood disorders are summarized in Table 3 and Figure 1.¹⁷ Treatments for subtypes of agitation are summarized in Table 4.

Management of Agitation in Dementia* *--Preferred medications for the treatment of subtypes of agitation are summarized in Table 4. FIGURE 1. General strategy for managing agitation in a patient with dementia. Adapted with permission from Treatment of agitation in older persons with dementia. The Expert Consensus Panel for Agitation in Dementia. Postgrad Med 1998 Apr;Spec No:1-88.

 

Patient and Caregiver Education and Support

Family education is critical for optimal management. An alliance between the family physician and the family, particularly the primary caregiver, is the principal means of ensuring that the physician's instructions are followed. A close working relationship also serves to minimize patient and caregiver distress.

TABLE 4 Preferred Medications for Subtypes of Agitation* Subtype Treatment Delirium (other than medication toxicity) Treat underlying medical condition. If medication is needed, consider typical antipsychotic. Depression Without psychosis: antidepressant With psychosis: antidepressant plus antipsychotic, or electroconvulsive therapy Psychosis Acute: atypical antipsychotic Long-term: atypical antipsychotic Anxiety Acute: benzodiazepine such as lorazepam (Ativan) or oxazepam (Serax) Long-term: buspirone (BuSpar) Insomnia Acute: trazodone (Desyrel); consider benzodiazepine such as temazepam (Restoril) or zolpidem (Ambien). Long-term: trazodone "Sundowning" Acute: trazodone Long-term: trazodone; consider typical or atypical antipsychotic. Aggression or anger Severe  Acute: typical or atypical antipsychotic  Long-term: divalproex sodium (Depakote) or atypical antipsychotic Mild  Acute: trazodone  Long-term: divalproex sodium, SSRI, trazodone, or buspirone Osteoarthritic pain Long-term: tricyclic antidepressant, SSRI, or trazodone SSRI = selective serotonin reuptake inhibitor. *--The first step is the implementation of environmental interventions; then drug therapy should be considered.

TABLE 5 Resources for Information on Alzheimer's Disease and Support for Patients and Caregivers Administration on Aging Telephone: 202-619-7501; 800-677-1116 (Eldercare Locator) Web site: www.aoa.dhhs.gov Alzheimer's Association Telephone: 800-272-3900 Web site: www.alz.org Alzheimer's Disease Education and Referral (ADEAR) Center Telephone: 800-438-4380 Web site: www.alzheimers.org/adear Family Caregiver Alliance Resource Center Telephone: 415-434-3388 Web site: www.caregiver.org National Association of Area Agencies on Aging* Telephone: 202-296-8130 Web site: www.n4a.org *--In addition, check local telephone directory for listing of referral agencies.

 

After Alzheimer's disease has been diagnosed, the family physician should meet with the patient and family to answer questions and provide information about the diagnosis, prognosis, future care needs, treatment options and, in appropriate cases, potential research participation.¹⁸ The Alzheimer's Association recommends that patients be told their diagnosis to facilitate their participation in advance planning.

The family physician can help caregivers by educating them about simplifying tasks and providing meaningful activities for patients with Alzheimer's disease. Comprehensive psychoeducational training for caregivers and the use of support groups and community resources for patients and caregivers may reduce caregiver stress, improve patient behavior, and defer patient institutionalization.¹⁹ Referral for support services should be a routine component of patient care (Table 5).

Physician Involvement During Alzheimer's Disease

Over the course of Alzheimer's disease, medical and ethical issues arise as the patient's disability increases, new behavioral disturbances emerge, and family reactions evolve. Continuous physician involvement is critical to aiding the family throughout the disease process. The family physician can help the patient and family make critical health care decisions by using a "values discussion" to encourage them to talk about difficult topics, enhancing their knowledge and understanding of health care procedures and care options, and helping them to develop successful problem-solving strategies and incorporate the wishes of all family members.²⁰

ADVANCE DIRECTIVES

A discussion of advance directives should be initiated as soon as possible after Alzheimer's disease is diagnosed, so that the patient can be involved to the greatest extent possible. The patient and family should be instructed to begin advance planning with regard to durable power of attorney, estate management, advance directives for management of the terminal stage of the disease, and determination of competency for making significant personal and economic decisions.^21,22 Surrogates should be appointed to make medical, financial, and legal decisions for incompetent patients.

TERMINAL CARE

Alzheimer's disease is a progressive and terminal illness. Loss of basic daily functional abilities is the hallmark of the final stage of the disease. The family physician has the difficult task of helping the family make decisions about terminal care. Early discussions about "do not resuscitate" orders, the use of antibiotics for infections, and the initiation of tube feeding will help the physician understand the beliefs and preferences of the patient and family.

Futile care that may not provide comfort and may prolong the dying process should be avoided. Hospice care can be invaluable for the family of a patient with end-stage Alzheimer's disease.

REPORTING REQUIREMENTS

Advancing Alzheimer's disease is correlated with a higher risk of traffic accidents. Many states encourage physicians and other service providers to report persons who have conditions that may affect their ability to drive safely. California is the only state with a specific public policy requiring the reporting of persons with Alzheimer's disease. Pennsylvania mandates the reporting of persons with any condition that would impair driving ability.

In all but seven states, health care and social service providers are required to report elder abuse. The states with voluntary reporting are Colorado, New Jersey, New York, North Dakota, Pennsylvania, and South Dakota. Laws about reporting and requirements concerning this reporting vary by state. The Web site for the National Center on Elder Abuse (www. elderabusecenter.org) provides links to individual states for specific information on reporting requirements and procedures.

During office visits, the family physician should be alert for unusual patient injuries, should assess caregiver distress and coping mechanisms, and should observe patient-caregiver interaction. Behavioral disturbances in the patient should be monitored and addressed, because behavioral symptoms are a predictor of elder abuse.²³

The authors indicate that they do not have any conflicts of interest. Sources of funding: Dr. Cummings has served as a consultant and conducted research for AstraZeneca L.P., Bayer Corporation, Janssen Pharmaceutica Products, L.P., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Parke-Davis, and Pfizer Inc. Dr. Frank has served as a consultant for Novartis Pharmaceuticals. This manuscript is based on work initiated by the Ad Hoc Standards of Care Committee of the Alzheimer's Disease Diagnostic and Treatment Centers of California and continued by the California Workgroup on Guidelines for Alzheimer's Disease Management Project. The work was supported in part by California's Department of Health Services under contracts no. 95-23557 and 00-91317, and by grant no. CSH000149-5 from the Federal Health Resources and Services Administration's Bureau of Primary Health Care and Administration on Aging, and the Los Angeles chapter of the Alzheimer's Association. The California Geriatric Education Center and the Center for the Study of Healthcare Provider Behavior have received subcontracts to assist the Alzheimer's Association. Members of the California Workgroup on Guidelines for Alzheimer's Disease Management Project have donated their time and expenses to improve the quality of care for patients with Alzheimer's disease and their families. Support was made available from the Alzheimer's Disease Center at the University of California, Los Angeles, under grant no. AG 16570, and from the Sidell-Kagan Foundation.

The authors acknowledge the members of the California Workgroup on Guidelines for Alzheimer's Disease Management, including members of the workgroup's executive committee (names in bold): Maria P. Aranda, Ph.D., Judy Canterbury, M.S.N., Debra Cherry, Ph.D., Michael Cushing, M.D., Richard Della Penna, M.D., Cordula Dick-Muehlke, Ph.D., Edith S. Eddleman-Robinson, L.C.S.W., Elizabeth Edgerly, Ph.D., Lynn Friss Feinberg, M.S.W., Janet Frank, Dr.P.H., Vicki Hart, L.C.S.W., Linda Hewett, Psy.D., Robert Hierholzer, M.D., James T. Howard, M.S., Roland Jacobs, M.D., Bryan Kemp, Ph.D., Neal Kohatsu, M.D., M.P.H., Kit Lackey, Daniel A. Lang, M.D., Kathryn Lowell, Joan Mengelkoch, M.A., Lydia Missaelides, M.H.A., Brian Mittman, Ph.D., Janet Morris, J.D., Laura Mosqueda, M.D., Kate O'Malley, R.N., Cheryl Phillips-Harris, M.D., Ann Quinones, M.P.A., R.N., Christine Rozance, M.D., Debra Saliba, M.D., M.P.H., Dan Schroepfer, Lynda Shelton, M.P.A., Steven Sproger, L.C.S.W., Ph.D., Dodie Tyrell, M.A., Barbara Vickrey, M.D., M.P.H., and Sharron Watts, M.P.A., as well as Kathryn Duke, Gene Giberson, Kara Kennedy, M.S.W., and Katie Maslow, M.S.W.

This is part II of a two-part article on Alzheimer's disease. Part I, "Assessment," appeared in the
June 1 issue (Am Fam Physician 2002;65: 2263-72).

---

REFERENCES

1. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, et al. Guidelines for managing Alzheimer's disease: Part I. Assessment. Am Fam Physician 2002;65:2263-72.
2. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: management of dementia (an evidence-based review). Neurology 2001;56:1154-66.
3. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-31.
4. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195-203.
5. Corey-Bloom J, Thal LJ, Galasko D, Folstein M, Drachman D, Raskind M, et al. Diagnosis and evaluation of dementia. Neurology 1995;45:211-8.
6. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54:2269-76.
7. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 1994;271:985-41.
8. Bowie P, Branton T, Holmes J. Should the Mini-Mental State Examination be used to monitor dementia treatments? Lancet 1999; 354:1527-8.
9. ano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
10. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000;283:1007-15.
11. Brauner DJ, Muir JC, Sachs GA. Treating nondementia illnesses in patients with dementia. JAMA 2000;283:3230-5.
12. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease Study. Am J Psychiatry 2000;157:1686-9.
13. Cohen-Mansfield J, Werner P. Longitudinal changes in behavioral problems in old age: a study in an adult day care population.
    J Gerontol A Biol Sci Med Sci 1998;53:M65-71.
14. Haupt M, Karger A, Janner M. Improvement of agitation and anxiety in demented patients after psychoeducative group intervention with their caregivers. Int J Geriatr Psychiatry 2000;15:1125-9.
15. Sultzer D, Cummings JL. Alzheimer's disease. In: Rakel RE, Conn HF, eds. Current therapy, 1993: latest approved methods of treatment for the practicing physician. Philadelphia: Saunders, 1993: 838-40.
16. Cummings JL, Askin-Edgar S. Evidence for psychotropic effects of acetylcholinesterase inhibitors. CNS Drugs 2000;13:385-95.
17. Treatment of agitation in older persons with dementia. The Expert Consensus Panel for Agitation in Dementia. Postgrad Med 1998 Apr;Spec No:1-88.
18. Post SG, Whitehouse PJ. Fairhill guidelines on ethics of the care of people with Alzheimer's disease: a clinical summary. Center for Biomedical Ethics, Case Western Reserve University and the Alzheimer's Association. J Am Geriatr Soc 1995;43:1423-9.
19. Mittleman MS, Ferris SH, Shulman E, Steinberg G, Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA 1996; 276:1725-31.
20. Roberto KA. Making critical health care decisions for older adults: consensus among family members. Fam Relations 1999;48:167-75.
21. Marson DC, Chatterjee A, Ingram KK, Harrell LE. Toward a neurologic model of competency: cognitive predictors of capacity to consent in Alzheimer's disease using three different legal standards. Neurology 1996;46:666-72.
22. Overman W Jr, Stoudemire A. Guidelines for legal and financial counseling of Alzheimer's disease patients and their families. Am J Psychiatry 1988;145:1495-500.
23. Coyne AC, Reichman WE, Berbig LJ. The relationship between dementia and elder abuse. Am J Psychiatry 1993;150:643-6.

---

---

---